NCT00892736

ABT-888 (Veliparib) in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy

Study identifier: NCT00892736
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Veliparib (Abbott)

Eligibility:

• Documented BRCA1/2 mutation AND a BRCA-related malignancy (e.g., primarily
  breast or ovarian cancer, but may include prostate or pancreatic cancer). Progressive disease after standard therapy OR no acceptable standard treatment options available.

Type of study:

Phase I

Treatment:

• Patients receive oral ABT-888 twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or toxicity.

Study site:

Pennsylvania

UPMC Cancer Center
Pittsburgh, Pennsylvania, 15232
Contact: Clinical Trials Office - UPMC Cancer Centers     412-647-8073  

Page updated 03/21/11

Web design by Rareheron Web Design